On Nov 21, major Wall Street analysts update their ratings for $argenx SE (ARGX.US)$, with price targets ranging from $606 to $770.
BofA Securities analyst Tazeen Ahmad maintains with a buy rating, and adjusts the target price from $670 to $717.
Evercore analyst Gavin Clark-Gartner maintains with a buy rating, and adjusts the target price from $436 to $706.
Stifel analyst Alex Thompson CFA maintains with a buy rating, and maintains the target price at $707.
Raymond James analyst Danielle Brill maintains with a buy rating, and adjusts the target price from $688 to $770.
H.C. Wainwright analyst Douglas Tsao maintains with a buy rating, and maintains the target price at $617.
Furthermore, according to the comprehensive report, the opinions of $argenx SE (ARGX.US)$'s main analysts recently are as follows:
Argenx's clinical proof-of-concept in myositis, with subQ efgart, has yielded statistically significant improvement across all three myositis subtypes evaluated in Phase 2. This development is seen as broadening Argenx's leadership in the autoimmune category, with expectations to reveal detailed results at an upcoming medical meeting.
Here are the latest investment ratings and price targets for $argenx SE (ARGX.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
